Announcing : the Peyronie’s Clinical Trial
The Whole Man: An Integrative Approach to the Treatment of Peyronie’s Disease
The P-Treatment by Dr. Deborah Dunn is conducting a clinical trial that incorporates mitochondrial oxidation status, Shockwave Treatment (LiEST), PRP (platelet rich plasma) Injections into plaque, pharmacology, nutritional supplements, and manual traction.
The trial begins December 2018, and the clinic is now performing consultations to qualify medical candidates.
Read on to learn about the study and contact us to find out if you might be a good candidate for this integrative study!
Brief Summary of Clinical Trial:
Treatments for Peyronie’s Disease have been limited and often unsuccessful. The goal of treatment is to reduce pain, remodel plaque, and increase sexual function satisfaction. While a variety of modalities show improvement, few studies have been conducted that interweave disparate targeted mechanisms of action into one comprehensive integrative treatment that harnesses synergy. Intralesional needling and injections have been used in scar tissue with some success, and their application into PD lesions has been used for over 50 years. Evidence on best outcomes result from treating phase 1, or the early stage disease. Use of prescriptive pharmacologics, supplements, intralesional treatments, and physical treatments have been used with varying success.
The latest work using LiEST (Low Intensity Shockwave Therapy) to break down scar tissue and return a subject to an earlier phase, is showing promising results. However, if the oxidative environment is unaddressed, realignment of the functional collagen and elastin will not be optimized. PRP independently and in combination with LiEST, has demonstrated positive findings. Oral antioxidants, antifibrotics, and herbals have been shown to alter wound healing of PD in a positive fashion. To our knowledge, no Integrative Study exists.